NeuroSync Company Profile

Background

NeuroSync, formerly known as SyncThink, is a neurotechnology company specializing in digital health platforms aimed at enhancing brain health assessment and treatment. Founded in 2008, the company rebranded to NeuroSync in September 2022 to reflect its expanded focus within the neurological healthcare market. NeuroSync's mission is to provide objective neurological measurements that assist medical and performance professionals in assessing brain health, delivering therapies, and enhancing cognitive function.

Key Strategic Focus

NeuroSync's strategic focus centers on developing and deploying advanced neurotechnology solutions that offer objective, rapid, and reliable assessments of brain health. The company's core objectives include:

Development of Proprietary Technologies: Creating innovative tools like EYE-SYNC and PRO-SYNC to assess and monitor neurological conditions.

Integration of Artificial Intelligence (AI): Leveraging AI to enhance the accuracy and efficiency of brain health diagnostics and therapeutics.

Expansion into Diverse Markets: Targeting healthcare, sports, biopharmaceuticals, and military sectors to broaden the application of its technologies.

By focusing on these areas, NeuroSync aims to address the significant need for validated, objective diagnostics and therapies for various neurological health conditions.

Financials and Funding

NeuroSync has secured multiple funding rounds to support its growth and technological advancements:

Series B Funding: In May 2023, the company initiated a Series B funding round, raising $10 million to further develop its neurotechnology platforms.

Series A Funding: In November 2020, NeuroSync completed a Series A funding round, the details of which have not been publicly disclosed.

Seed Rounds and Grants: The company has also benefited from seed funding and grants, including a $36 million grant in 2012, to support its research and development initiatives.

Notable investors include Kevin Quinn, Mitsubishi Chemical Advanced Materials, Oceanic Partners, StartUp Health, and Plug and Play Tech Center.

Pipeline Development

NeuroSync's product pipeline features key technologies at various stages of development:

EYE-SYNC: An FDA-cleared eye-tracking technology used for assessing ocular motor impairments and ocular vestibular dysfunction. It is currently utilized by leading university athletic departments and medical clinics, including Stanford University and Massachusetts General Hospital.

PRO-SYNC: An AI-driven brain performance optimization solution designed for sports teams and athletes, launched in September 2022.

ADHD Biomarker Identification Platform: NeuroSync is sponsoring ongoing clinical studies to develop a biomarker identification platform for Attention Deficit Hyperactivity Disorder (ADHD), aiming to expand the reach and impact of its technology across the neuro health market.

Technological Platform and Innovation

NeuroSync distinguishes itself through its proprietary technologies and innovative methodologies:

Proprietary Technologies: The company's flagship product, EYE-SYNC, utilizes integrated head-mounted eye-tracking devices to assess and monitor neurological conditions such as concussions, traumatic brain injuries (TBI), ADHD, dizziness, imbalance, stroke, fatigue, and neurodegenerative diseases.

Scientific Methodologies: NeuroSync employs advanced eye-tracking metrics and AI-driven analytics to provide objective data for clinicians and researchers, enhancing the accuracy and efficiency of brain health diagnostics.

AI-Driven Capabilities: The integration of AI into NeuroSync's platforms allows for rapid, accurate, and reliable assessments, facilitating better patient outcomes and performance optimization.

Leadership Team

NeuroSync's leadership comprises experienced professionals dedicated to advancing neurotechnology:

Gary Gregory: Chief Executive Officer, President, and Chairman. Appointed in 2022, Gregory brings extensive experience in leading technology companies and driving strategic growth.

Jamshid Ghajar, MD, PhD: Founder and Chief Scientific Officer. Dr. Ghajar is a neurosurgeon and neuroscientist with a focus on brain injury and recovery.

Scott Anderson: Chief Clinical Officer and Product Lead. Anderson oversees clinical operations and product development, ensuring the alignment of NeuroSync's offerings with clinical needs.

John Mattiola: Chief Business Officer. Mattiola is responsible for business development and strategic partnerships, driving the company's market expansion efforts.

Leadership Changes

In 2022, NeuroSync appointed Gary Gregory as Chief Executive Officer, President, and Chairman, marking a significant leadership change aimed at accelerating the company's growth in the neurological healthcare market.

Competitor Profile

Market Insights and Dynamics

The neurotechnology market is experiencing significant growth, driven by increasing awareness of neurological health and the demand for objective diagnostic tools. The market encompasses various applications, including healthcare, sports, biopharmaceuticals, and military sectors, with a focus on improving brain health assessment and treatment.

Competitor Analysis

NeuroSync faces competition from several companies in the neurotechnology space:

BrainScope: A venture capital-backed company based in Chevy Chase, MD, specializing in brain health assessment tools.

Oculogica: Located in New Richmond, WI, Oculogica develops eye-tracking technologies for neurological assessments.

RightEye: Based in Bethesda, MD, RightEye offers eye-tracking solutions for health and wellness applications.

These competitors focus on various aspects of neurotechnology, including eye-tracking and brain health assessments, contributing to a dynamic and evolving market landscape.

Strategic Collaborations and Partnerships

NeuroSync has established significant collaborations to enhance its market position and innovation capacity:

Magic Leap Partnership: In February 2022, NeuroSync partnered with augmented reality leader Magic Leap to co-develop a platform for vestibular disorders, expanding its technological capabilities.

European Market Expansion: In August 2022, EYE-SYNC received CE Mark certification, enabling NeuroSync to commercialize its efforts in Europe and broaden its global reach.

Operational Insights

NeuroSync's strategic considerations include:

Market Positioning: Leveraging its FDA-cleared technologies and AI-driven platforms to establish a strong presence in the neurotechnology market.

Competitive Advantages: Offering rapid, accurate, and reliable assessments through proprietary technologies, differentiating itself from competitors.

Diversified Applications: Targeting multiple sectors, including healthcare, sports, biopharmaceuticals, and military, to maximize the impact and adoption of its technologies.

Strategic Opportunities and Future Directions

NeuroSync's strategic roadmap includes:

Product Development: Advancing existing technologies like EYE-SYNC and PRO-SYNC, and developing new solutions to address a broader range of neurological conditions.

Market Expansion: Strengthening its presence in international markets, particularly in Europe, following CE Mark certification.

Research and Innovation: Continuing to invest in research and development to maintain technological leadership and address emerging needs in brain health assessment and treatment.

Contact Information

Website: www.neurosync.health

Headquarters: Holliston, MA, USA

NeuroSync's commitment to innovation and objective neurological measurements positions it as a leader in the neurotechnology industry, dedicated to transforming brain health assessment and treatment across various sectors.